Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.49 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135587 | 0.85 | LMNA (0.51) | ALDH1A1RAB9ALMNATDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL5071263 | 0.83 | LMNA (0.52) | ALDH1A1RAB9ALMNATDP1CYP1A2 | |
| SCHEMBL3689477 | 0.81 | LMNA (0.51) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL171395 | 0.80 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1MEN1KMT2AHTR2A | |
| SCHEMBL64206 | 0.79 | POLB (0.64) | ALDH1A1RAB9AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL3307413 | 0.79 | ALDH1A1 (0.63) | ALDH1A1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3682133 | 0.79 | BCHE (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL3682132 | 0.79 | MAPT (0.59) | ALDH1A1RAB9AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL30383292 | 0.79 | BCHE (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL3684640 | 0.79 | MAPT (0.59) | ALDH1A1RAB9AHPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100441556-C | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL LTD (FI) | 2008-12-10 | — | — | CN | disclosed |
| CN-1861555-A | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL LTD (FI) | 2006-11-15 | — | — | CN | disclosed |
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| CN-1263720-C | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2006-07-12 | — | — | CN | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
| CN-1399622-A | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2003-02-26 | — | — | CN | disclosed |
| EP-1235776-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Hormos Medical Corporation (FI) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001036360-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORPORATION (FI) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | ALDH1A1 2679/4885MAPK13 2532/4885MAPK12 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.